Incyte (INCY) Short term Debt (2012 - 2026)
Incyte's (INCY) quarterly Short term Debt came in at $38.8 million in Q2 2026, down 17.14% YoY from $46.8 million in Q2 2025, and down 1.45% on a QoQ basis from $39.4 million in Q1 2026.
Incyte (INCY) Short term Debt (2012 - 2026) Analysis & Trends
Incyte (INCY) has 14 years of Short term Debt data on file, last reported at $38.8 million in Q2 2026.
- Quarterly Short term Debt fell 17.14% year-over-year to $38.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $38.8 million (down 17.14% YoY) and the FY2025 annual result came in at $41.1 million, up 4.86% from the prior year.
- Short term Debt fell to $38.8 million in Q2 2026, from $39.4 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $46.8 million in Q2 2025 to a low of $34.2 million in Q3 2022.
- A 5-year average of $39.0 million and a median of $38.1 million in 2022 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2025 — Short term Debt advanced 26.07% — and 2026, when it fell 17.14%.
- Tracing INCY's Short term Debt over 5 years: stood at $36.5 million in 2022, then increased by 5.16% to $38.4 million in 2023, then increased by 2.12% to $39.2 million in 2024, then advanced by 4.86% to $41.1 million in 2025, then retreated by 5.67% to $38.8 million in 2026.
- The last three Short term Debt figures came in at $38.8 million (Q2 2026), $39.4 million (Q1 2026), and $41.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.81 Mn |
| Mar 31, 2026 | 39.38 Mn |
| Dec 31, 2025 | 41.14 Mn |
| Sep 30, 2025 | 45.62 Mn |
| Jun 30, 2025 | 46.84 Mn |
| Mar 31, 2025 | 41.72 Mn |
| Dec 31, 2024 | 39.24 Mn |
| Sep 30, 2024 | 40.34 Mn |
| Jun 30, 2024 | 37.16 Mn |
| Mar 31, 2024 | 37.16 Mn |
| Dec 31, 2023 | 38.42 Mn |
| Sep 30, 2023 | 36.82 Mn |
| Jun 30, 2023 | 37.51 Mn |
| Mar 31, 2023 | 37.17 Mn |
| Dec 31, 2022 | 36.54 Mn |
| Sep 30, 2022 | 34.19 Mn |
| Jun 30, 2022 | 36.92 Mn |
| Mar 31, 2022 | 37.87 Mn |
| Dec 31, 2021 | 37.01 Mn |
| Sep 30, 2021 | 38.22 Mn |